

**METHODS OF USE OF BCL-6-DERIVED NUCLEOTIDES TO INDUCE  
APOPTOSIS**

**CROSS REFERENCE TO RELATED APPLICATION**

5 [0001] This application claims priority of United States Provisional Application serial number 60/555,207, filed March 22, 2004, which is hereby incorporated in its entirety by reference herein.

**STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR  
DEVELOPMENT**

10 [0002] The invention described herein was supported in part by a grant from The National Institutes of Health (Grant No. PO1-CA72765). The U.S. Government may have certain rights in this invention.

**FIELD OF INVENTION**

15 [0003] This invention provides methods of inducing apoptosis in a bcl-6-expressing cell and methods of treating a subject with a cancer comprising a bcl-6-expressing cell, comprising administration of a composition that reduces the amount of the bcl-6 protein or of an mRNA molecule encoding same, a composition comprising a nucleic acid molecule  
20 complementary to or corresponding to a region of the mRNA molecule, or a vector expressing the nucleic acid molecule. In another embodiment, the present invention provides an isolated nucleic acid molecule having a sequence corresponding to or complementary to accessible regions of bcl-6 mRNA, and vectors, cells, compositions, and kits comprising same.

### **BACKGROUND OF THE INVENTION**

[0004] BCL-6 is a zing finger protein that acts as a sequence-specific transcriptional repressor, binding to DNA with its amino-terminal Pox virus zinc finger (POZ) domain. Bcl-6 is frequently deregulated in non-Hodgkin lymphomas. The altered expression of Bcl-6  
5 arises mostly from 3q27 translocations, in which the 5' non-coding region is replaced by a heterologous promoter, leading to over-expression of the protein.

[0005] The term "lymphoma" encompasses more than 40 related types of cancer that develop from lymphocytes (cells of the immune system). Lymphoma arises when one of these cells undergoes a transformation into a malignant cell and begins to grow abnormally,  
10 dividing and forming tumors. Lymphomas are divided into two general types: Hodgkin's disease and non-Hodgkin's lymphomas.

### **SUMMARY OF THE INVENTION**

[0006] This invention provides methods of inducing apoptosis in a bcl-6-expressing cell and methods of treating a subject with a cancer comprising a bcl-6-expressing cell,  
15 comprising administration of a composition that reduces the amount of the bcl-6 protein or of an mRNA molecule encoding same, a composition comprising a nucleic acid molecule complementary to or corresponding to a region of the mRNA molecule, or a vector expressing the nucleic acid molecule. In another embodiment, the present invention provides an isolated nucleic acid molecule having a sequence corresponding to or complementary to  
20 accessible regions of bcl-6 mRNA, and vectors, cells, compositions, and kits comprising same.

[0007] In one embodiment, the present invention provides a method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting the bcl-6-expressing cell with a composition that reduces an amount of the bcl-6 protein or of a ribonucleic acid (RNA)  
25 molecule encoding the bcl-6 protein, thereby inducing apoptosis in a bcl-6-expressing cell.

[0008] In another embodiment, the present invention provides a method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting the bcl-6-expressing cell with a composition comprising a nucleic acid molecule complementary to a region of a RNA molecule encoding the bcl-6 protein, thereby inducing apoptosis in a bcl-6-expressing cell.

5 [0009] In another embodiment, the present invention provides a method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting the bcl-6-expressing cell with a composition comprising a nucleic acid molecule corresponding to a region of a RNA molecule encoding the bcl-6 protein, thereby inducing apoptosis in a bcl-6-expressing cell.

10 [0010] In another embodiment, the present invention provides a method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting the bcl-6-expressing cell with a vector expressing a nucleic acid molecule complementary to a region of a RNA molecule encoding the bcl-6 protein, thereby inducing apoptosis in a bcl-6-expressing cell.

15 [0011] In another embodiment, the present invention provides a method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting the bcl-6-expressing cell with a vector expressing a nucleic acid molecule corresponding to a region of a RNA molecule encoding the bcl-6 protein, thereby inducing apoptosis in a bcl-6-expressing cell.

20 [0012] In another embodiment, the present invention provides a method of treating a subject with a cancer comprising a bcl-6-expressing cell, comprising contacting the subject with a composition that reduces an amount of the bcl-6 protein or of a RNA molecule encoding the bcl-6 protein, thereby treating a subject with cancer comprising a bcl-6-expressing cell.

25 [0013] In another embodiment, the present invention provides a method of treating a subject with a cancer comprising a bcl-6-expressing cell, comprising contacting the subject with a composition comprising a nucleic acid molecule complementary to a region of a RNA molecule encoding the bcl-6 protein, thereby treating a subject with cancer comprising

a bcl-6-expressing cell.

[00014] In another embodiment, the present invention provides a method of treating a subject with a cancer comprising a bcl-6-expressing cell, comprising contacting the subject with a composition comprising a nucleic acid molecule corresponding to a region of a RNA molecule encoding the bcl-6 protein, thereby treating a subject with cancer comprising a bcl-6-expressing cell.

[00015] In another embodiment, the present invention provides a method of treating a subject with a cancer comprising a bcl-6-expressing cell, comprising contacting the subject with a vector expressing a nucleic acid molecule complementary to a region of a RNA molecule encoding the bcl-6 protein, thereby treating a subject with cancer comprising a bcl-6-expressing cell.

[00016] In another embodiment, the present invention provides a method of treating a subject with a cancer comprising a bcl-6-expressing cell, comprising contacting the subject with a vector expressing a nucleic acid molecule corresponding to a region of a RNA molecule encoding the bcl-6 protein, thereby treating a subject with cancer comprising a bcl-6-expressing cell.

[00017] In another embodiment, the present invention provides an isolated nucleic acid molecule having a sequence selected from the sequences set forth in SEQ ID No: 1-10. In another embodiment, the present invention provides an isolated nucleic acid molecule having a sequence complementary to a sequence selected from the sequences set forth in SEQ ID No: 1-10.

### **BRIEF DESCRIPTION OF THE FIGURES**

[00018] Figure 1. SQRM design and reaction. (a) Concept: to exploit the traditional stem-loop structure of the SQRMs, a computer algorithm searched an entire sequence of mRNA

for complementary sequences of a desired length (stems) that are separated by a proscribed distance (loop). (b) Chemistry: the complementary sequences were synthesized as SQRM possessing 50-fluorescein and 30 DABCYL groups. In the absence of target, quenching of fluorescence occurs. Once hybridization of the loop sequence to a complementary target  
5 takes place, the moieties are separated and fluorescence can be detected.

[00019] Figure 2. Fluorescence of SQRM molecules upon incubation with bcl-6 mRNA. Six SQRMs were hybridized with *in vitro*-transcribed human bcl-6 targeted mRNA (2.4 kb). Of these SQRMs, 1190-1222 was shown to open, exhibiting a signal-to-noise ratio of 15:1. Light bars; SQRM alone; dark bars; SQRM + RNA.

10 [00020] Figure 3. A. Use of *in vitro* RNaseH cleaving assay to confirm hybridization of SQRM 1190-1222 with the bcl-6 transcript. Bcl-6 mRNA was incubated with RNaseH and SQRM 831 (lane 2), RNaseH and 1190-1222 (lane 3), RNaseH and 1367 (lane 4), nothing (lane 5), or RNaseH alone (lane 6). B. bcl-6 SQRM 1190-1222 was incubated with various targets and the fluorescence signal was measured. Louckes-1 (20 mg), Louckes-2 (40 mg)  
15 and K562 are RNA samples isolated from cell extracts. SQRM was also incubated with *in vitro* transcribed RNA (IVT RNA; a positive control for SQRM/RNA hybridization) and an ODN (positive control for SQRM function).

[00021] Figure 4. Transfection efficiency of ODN or siRNA by nucleoporation. Left panel: phase contrast microscope. Right panel: Fluorescence microscope, used to detect uptake of  
20 fluorescein-labeled ODN.

[00022] Figure 5. Effect of bcl-6-derived ODN on the viability of bcl-6-expressing lymphoma cells.

[00023] Figure 6. Effect of bcl-6-derived ODN on bcl-6 mRNA expression in lymphoma

cells.

[00024] Figure 7. Effect of bcl-6-derived ODN on bcl-6 protein expression in lymphoma cells. Lanes from left to right: positive control ODN; SQRM 1190-1222; SQRM 1367; SQRM 1816; scrambled; SQRM 831-864; SQRM 2121-2141.

5 [00025] Figure 8. Effect of bcl-6-derived siRNA on bcl-6 mRNA expression in lymphoma cells.

[00026] Figure 9. Effect of bcl-6-derived siRNA on bcl-6 protein expression in lymphoma cells.

10 [00027] Figure 10. shRNA reduction of Bcl-6 and induction of apoptosis in diffuse large B-cell lymphoma (DLBCL) cells. A: Fold reduction of Bcl-6 mRNA in GFP-virus vs. shRNA-GFP-virus- infected Ly7 cells compared to control cells. Values are normalized to HPRT as an internal standard mRNA. B: percent of Ly7 cells undergoing apoptosis after 48 hours post-infection. Depicted are control cells, and cells infected with GFP-virus and shRNA-GFP-virus cells.

15

#### **DETAILED DESCRIPTION OF THE INVENTION**

[00028] This invention provides methods of inducing apoptosis in a bcl-6-expressing cell and methods of treating a subject with a cancer comprising a bcl-6-expressing cell, comprising administration of a composition that reduces the amount of the bcl-6 protein or of an mRNA molecule encoding same, a composition comprising a nucleic acid molecule complementary to or corresponding to a region of the mRNA molecule, or a vector expressing the nucleic acid molecule. In another embodiment, the present invention provides an isolated nucleic acid molecule having a sequence corresponding to or complementary to accessible regions of bcl-6 mRNA, and vectors, cells, compositions, and kits comprising same.

20

[00029] In one embodiment, the present invention provides a method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting the bcl-6-expressing cell with a composition that reduces an amount of the bcl-6 protein or of a ribonucleic acid (RNA) molecule encoding the bcl-6 protein, thereby inducing apoptosis in a bcl-6-expressing cell.

5 [00030] In one embodiment, the phrase "bcl-6 expressing" means that the cell expresses bcl-6 mRNA. In another embodiment, the phrase "bcl-6 expressing" means that the cell expresses bcl-6 protein. Methods of detecting expression of an mRNA are well known in the art, and include reverse transcription/ polymerase chain reaction (PCR; Example 2), Western blotting (Example 2), fluorescence-activated cell sorting (FACS), and others. These methods  
10 are described, for example, in Sambrook et al., 2001, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, NY. Each method represents a separate embodiment of the present invention.

[00031] In another embodiment, the present invention provides a method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting the bcl-6-expressing cell with a  
15 composition comprising a nucleic acid molecule complementary to a region of a RNA molecule encoding the bcl-6 protein, thereby inducing apoptosis in a bcl-6-expressing cell. In one embodiment, the region is an accessible region as defined herein.

[00032] As provided herein, the results demonstrate that bcl-6 contains regions that are available for hybridization, and that hybridization of complementary oligonucleotides to  
20 such regions of bcl-6 messenger RNA (mRNA) reduces levels of bcl-6 mRNA and bcl-6 protein and induces apoptosis in lymphoma cells.

[00033] In one embodiment, the bcl-6 transcript or mRNA of methods and compositions of the present invention has the sequence:

ggccctcgagcctcgaaccggaacctccaaatccgagacgctctgcttatgaggacctc gaaatatgccggccagtgaaaaaatct  
25 tatggctttgagggcttttggttgccaggggcagtaaaaatctcggagagctgacaccaa gtcctccctgccacgtacgtggta

aagtccgaagctcaaattccgagaattgagctctgttgattcttgaactgggggttcttagaagtggatgcaagaagttttaggaaa  
ggccggacaccagggtttgagcaaaatttggactgtgaagcaaggcattgggtgaagacaaaaatggcctcgcgggctgacagctgtat  
ccagttcaccgcatgccagtgttcttcaaccttaatcgtctccggagtcgagacatcttgactgatgtgtcattgttgtagcc  
gtgagcagtttagagcccataaaacggctcctcatggcctgcagtggcctgttctatagcatctttacagaccagttgaaatgcaacctta  
5 gtgtgatcaatctagatcctgagatcaaccctgagggattctgcatcctcctggacttcatgtacacatctcggctcaatttgcgggagg  
gcaacatcatggctgtgatggccacggctatgtacctgcagatggagcatgttgggacacttgcgggaagttattaaggccagtga  
gcagagatggtttctgccatcaagcctcctcgtgaagagttcctcaacagccggatgctgatgccccaaagacatcatggcctatcggg  
gtcgtgaggtgggtggagaacaacctgccactgaggagcggcctgggtgtgagagcagagccttgcggccagcctgtacagtggc  
ctgtccacaccgccagcctcttattccatgtacagccacctccctgtcagcagcctcctcttctccgatgaggagtttgggatgtccgg  
10 atgcctgtggccaaccccttcccaaggagcgggactcccatgtgatagtccaggccagtcctgggtgagtacagccggccgac  
tttgaggtgtccccaatgtgtgccacagcaatatctattcaccgaaggaaacaatcccagaagaggcacgaagtgatatgcactac  
agtgtggctgagggcctcaaacctgctgccccctcagcccgaaatgccccctacttccctgtgacaaggccagcaagaagaaga  
gagacctcctcgggaagatgagattgcccctgcatttcgagcccccaatgcacccctgaaccggaagggtctggtagtccacagag  
ccccagaaatctgactgccagcccaactgcccacagaggcctgcagcagtaagaatgcctgcatcctccaggcttctggctccc  
15 tccagccaagagccccactgaccccaaagcctgcaactggaagaaatacaagttcatcgtgtcaacagcctcaaccagaatgcc  
aaccaggggggctgagcaggctgagctgggcgccttccccacgagcctacacggccccacctgctgccagccacctatgga  
gcttgagaaccttgacctccagtccccaaccaagctgagtgccagcggggaggactccaccatcccacaagccagccggctcaat  
aacatcgttaacaggctccatgacgggctctccccgcagcagcagcgagagccactcaccactctacatgcacccccgaagtgcac  
gtcctgcggctctcagtcccccacagcatgcagagatgtgcctccacaccgtggccccacgttcgctgaggagatgggagagacc  
20 agtctgagtactcagattctagctgtgagaacggggccttcttctgcaatgagtgtgactgccgcttcttgaggaggcctcactcaaga  
ggcacacgctgcagaccacagtgcacaaacctacaagtgtgaccgctgccaggcctcctccgctacaagggcaacctgcggag  
ccacaagaccgtccataccgggtgagaaacctatcgttgcaacatctgtggggcccagttcaaccggccagccaacctgaaaacc  
acactcgaattcactctggagagaagccctacaaatgcgaaacctgcggagccagattgtacaggtggccacctccgtgcccatgt  
gcttatccacactgggtgagaagccctatccctgtgaaatctgtggcaccogtttccggcaccttcagactctgaagagccacctgcgaa  
25 tccacacaggagagaaaccttaccattgtgagaagtgtaacctgcatttccgtcacaaaaggcagctgcgacttcacttgcgccagaa  
gcatggcgccatcaccaacaccaaggtgcaataccgctgtcagccactgacctgcctccggagctcccaaaagcctgctgaagca  
tggagtgttgatgcttctcagcccccttctcagaatctacccaaaggatactgtaaacactttacaatgttcatcccatgatgtatgc



ctctttcatccactagtgc aaatcatagctgggggttgggggtgggtgggggtcggggcctgggggactgggagccgcagcagctcc  
 cctccccactgccataaaacattaagaaaatcatattgcttcttctctatgtgtaagggtgaaccatgtcagcaaaaagcaaatcattt  
 tatatgtcaaagcaggggagtatgcaaaagtctgacttgactttagctctgcaaatgaggaatgtatatgtttgtgggaacagatgtttc  
 tttgtatgtaaatgtcattcttttaaagacaagacttcagtatgttgtaaaagagagggcttaattttttaacaaaaggtgaaggaata  
 5 tatggcagagttgtaaatatataaatatataatataaaaataaatatataaaacctaacaagatatatfaaaaataaaaactgcgttaa  
 aggctcgattttgtatctgcaggcagacacggatctgagaatctttattgagaagagcacttaagagaatatttaagtattgcatctgta  
 taagtaagaaaatattttgtctaaatgcctcagtgtattgtattttttgcaagtgaaggtttacaatttacaagtggtattaaaaaaaac  
 ccaagaacccaaaaatctgcagaaggaaaaatgttaattttgttctagttttcagtttgatatatacccgtaaacgtgtcctcacgggtgc  
 ctttttcacggaagttttcaatgatgggcgagcgtgcaccatcccttttgaagtgtaggcagacacagggactgaagttgttactaact  
 10 aaactctctttgggaatgtttgtctcatccattctgcgtcatgctgtgtgataactactccggagacagggtttgctgtgtctaaactgc  
 attaccgctgtgtaaaaaatagctgtaccaatataagaataaaatgttggaaagtcgcaaaaaaaaaaaaaa (GenBank  
 Accession Number U00115; SEQ ID No: 11).

[00034] In another embodiment, the bcl-6 transcript is represented by any of GenBank  
 Accession Numbers NM\_138931, NM\_001706, NM\_017745, NM\_020926, AY316592,  
 15 AK074286, AF317392, and AF317391. In another embodiment, the bcl-6 transcript  
 comprises a sequence disclosed in any of GenBank Accession Numbers AF240680,  
 AF240681, D38312, Z79581, and AF191831. In another embodiment, the bcl-6 transcript is  
 represented by or contains any other bcl-6 sequence known in the art. In another  
 embodiment, the bcl-6 transcript is a long isoform transcript. In another embodiment, the  
 20 bcl-6 transcript is a short isoform transcript. In another embodiment, the bcl-6 transcript is  
 spliced. In another embodiment, the bcl-6 transcript is not spliced. In another embodiment,  
 the bcl-6 transcript is partially spliced. Each bcl-6 transcript represents a separate  
 embodiment of the present invention.

[00035] In another embodiment, the bcl-6 transcript is a result of a translocation of the bcl-6  
 25 gene to another gene or region, e.g. the switch region ( $S_H$ ) of the IgH locus. In one  
 embodiment, the translocation comprises a sequence disclosed in any of GenBank

Accession Numbers AJ557805 and AJ557817. In another embodiment, the bcl-6 transcript is a translocation of the bcl-6 gene to another gene or region. Each possibility represents a separate embodiment of the present invention.

[00036] In one embodiment, the complementary sequence is  
5 AGGCTGAGCTGGGCCGCCTTTCCCCACGAGCCT (segment 1190; SEQ ID No: 6). As shown in Example 1, an ODN corresponding to this sequence was able to bind bcl-6 RNA.

[00037] In another embodiment, the complementary sequence is  
GCTCTCCCCGCAGCAGCAGCGAGAGC (segment 1367; SEQ ID No: 7). In another  
embodiment, the complementary sequence is AAGCATGGAGTGTTGATGCTT (segment  
10 2121; SEQ ID No: 10). As shown in Examples 2 and 3, antisense deoxynucleotides (ODN) corresponding to SQRM 1367, 1190, and 2121, and short interfering RNA (siRNA) corresponding to the complementary bcl-6 mRNA sequence, decreased the bcl-6 expression and reduced the viability of lymphoma cells. Thus, such nucleotides have utility in inducing apoptosis in bcl-6 expressing cells and treating lymphomas.

15 [00038] In another embodiment, the complementary sequence is  
GCTGAGGGCCTCAAACCTGCTGCCCCCTCAGC (segment 831; SEQ ID No: 4). In another embodiment, the complementary sequence is any of the other target sequences listed in Table 1.

[00039] In another embodiment, the present invention provides a method of inducing  
20 apoptosis in a bcl-6-expressing cell, comprising contacting the bcl-6-expressing cell with a composition comprising a nucleic acid molecule corresponding to a region of an RNA molecule encoding the bcl-6 protein, thereby inducing apoptosis in a bcl-6-expressing cell. As shown in Example 3, administration of siRNA corresponding to regions of bcl-6 mRNA decreased the bcl-6 expression and reduced the viability of lymphoma cells.

25 [00040] In another embodiment, the present invention provides a method of inducing

apoptosis in a bcl-6-expressing cell, comprising contacting the bcl-6-expressing cell with a vector expressing a nucleic acid molecule complementary to a region of a RNA molecule encoding the bcl-6 protein, thereby inducing apoptosis in a bcl-6-expressing cell.

5 [00041] In another embodiment, the present invention provides a method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting the bcl-6-expressing cell with a vector expressing a nucleic acid molecule corresponding to a region of a RNA molecule encoding the bcl-6 protein, thereby inducing apoptosis in a bcl-6-expressing cell.

10 [00042] Methods of detecting apoptosis are well known in the art, and include trypan blue staining (Example 2), ethidium bromide/ acridine orange staining (Example 4), TUNEL assay, magnetic resonance (Brindle KM, Br J Radiol 76 Spec No 2:S111-7, 2003), and the use of radioactive ligands (Lahorte CM et al, Eur J Nucl Med Mol Imaging 31(6):887-919, 2004), and are described, for example, in Mirakian R et al, J Immunol Methods 265(1-2):161-75, 2002. Each method represents a separate embodiment of the present invention.

15 [00043] In one embodiment, the target cell of methods of the present invention is a lymphoma cell. In another embodiment, the cell is a non-Hodgkin's lymphoma cell. In another embodiment, the cell is a type of cancer cell other than lymphoma. In another embodiment, the cell is any other type of cell that expresses bcl-6 protein or mRNA. Each possibility represents a separate embodiment of the present invention.

20 [00044] In another embodiment, the present invention provides a method of treating a subject with a cancer comprising a bcl-6-expressing cell, comprising contacting the subject with a composition that reduces an amount of the bcl-6 protein or of a RNA molecule encoding the bcl-6 protein, thereby treating a subject with cancer comprising a bcl-6-expressing cell.

25 [00045] In another embodiment, the present invention provides a method of treating a subject with a cancer comprising a bcl-6-expressing cell, comprising contacting the subject

with a composition comprising a nucleic acid molecule complementary to a region of a RNA molecule encoding the bcl-6 protein, thereby treating a subject with cancer comprising a bcl-6-expressing cell.

5 [00046] In another embodiment, the present invention provides a method of treating a subject with a cancer comprising a bcl-6-expressing cell, comprising contacting the subject with a composition comprising a nucleic acid molecule corresponding to a region of a RNA molecule encoding the bcl-6 protein, thereby treating a subject with cancer comprising a bcl-6-expressing cell.

10 [00047] In another embodiment, the present invention provides a method of treating a subject with a cancer comprising a bcl-6-expressing cell, comprising contacting the subject with a vector expressing a nucleic acid molecule complementary to a region of a RNA molecule encoding the bcl-6 protein, thereby treating a subject with cancer comprising a bcl-6-expressing cell.

15 [00048] In another embodiment, the present invention provides a method of treating a subject with a cancer comprising a bcl-6-expressing cell, comprising contacting the subject with a vector expressing a nucleic acid molecule corresponding to a region of a RNA molecule encoding the bcl-6 protein, thereby treating a subject with cancer comprising a bcl-6-expressing cell.

20 [00049] In one embodiment, the cancer is a lymphoma. In another embodiment, the cancer is another cancer. Each possibility represents a separate embodiment of the present invention. As shown in Example 4, lentiviruses expressing short hairpin sequences complementary to bcl-6 mRNA decrease viability of lymphoma cells and their bcl-6 expression. Thus, such lentiviruses have utility in treating lymphoma.

25 [00050] A large number of vectors known in the art may be used in methods and compositions of the present invention. A vector may include, in some embodiments, an

appropriate selectable marker. In other embodiments, the vector may further include an origin of replication, or may be a shuttle vector, which can propagate both in bacteria, such as, for example, *E. coli* (wherein the vector comprises an appropriate selectable marker and origin of replication) or be compatible for propagation in vertebrate cells, or integration in the genome of an organism of choice. The vector according to this aspect of the present invention may be, for example, a plasmid, a bacmid, a phagemid, a cosmid, a phage, a modified or unmodified virus, an artificial chromosome, or any other vector known in the art. Many such vectors are commercially available, and their use is well known to those skilled in the art (see, for example, *Molecular Cloning*, (2001), Sambrook and Russell, eds.).

Each vector represents a separate embodiment of the present invention.

[00051] In another embodiment, the nucleotide molecule present in the vector may be a plasmid, cosmid, or the like, or a vector or strand of nucleic acid. In another embodiment, the nucleotide molecule may be genetic material of a living organism, virus, phage, or material derived from a living organism, virus, or phage. The nucleotide molecule may be, in one embodiment, linear, circular, or concatemerized, and may be of any length. Each type of nucleotide molecule represents a separate embodiment of the present invention.

[00052] In another embodiment, nucleic acid vectors comprising the isolated nucleic acid sequence include a promoter for regulating expression of the isolated nucleic acid. Such promoters are known to be cis-acting sequence elements required for transcription, as they serve to bind DNA-dependent RNA polymerase, which transcribes sequences present downstream thereof. Each vector represents a separate embodiment of the present invention.

[00053] In one embodiment, the isolated nucleic acid is subcloned into the vector. "Subcloning" refers, in one embodiment, to inserting an oligonucleotide into a nucleotide molecule. In one embodiment isolated DNA encoding an RNA transcript is inserted into an appropriate expression vector that is suitable for the host cell such that the DNA is transcribed to produce the RNA.

[00054] The insertion into a vector can, in another embodiment, be accomplished by ligating the DNA fragment into a vector that has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules are, in another embodiment, enzymatically modified.

5 Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. Methods for subcloning are known to those skilled in the art, and are described, for example in Molecular Cloning, (2001), Sambrook and Russell, eds. Each method represents a separate

10 embodiment of the present invention.

[00055] In one embodiment, the lymphoma is a follicular lymphoma. In another embodiment, the lymphoma is a Burkitt's lymphoma/Burkitt's cell leukemia. In another embodiment, the lymphoma is a diffuse large B-cell lymphoma. In another embodiment, the lymphoma is a precursor B-cell neoplasm. In another embodiment, the lymphoma is a

15 mature (peripheral) B-cell neoplasm. In another embodiment, the lymphoma is a B-cell chronic lymphocytic leukemia / small lymphocytic lymphoma. In another embodiment, the lymphoma is a B-cell prolymphocytic leukemia. In another embodiment, the lymphoma is a lymphoplasmacytic lymphoma. In another embodiment, the lymphoma is a splenic marginal zone B-cell lymphoma, including villous lymphocytes. In another embodiment, the

20 lymphoma is a splenic marginal zone B-cell lymphoma, not including villous lymphocytes. In another embodiment, the lymphoma is a nodal marginal zone lymphoma, including monocytoid B-cells. In another embodiment, the lymphoma is a nodal marginal zone lymphoma, not including monocytoid B-cells. In another embodiment, the lymphoma is an extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue

25 (MALT) type. In another embodiment, the lymphoma is a hairy cell leukemia. In another embodiment, the lymphoma is a plasma cell myeloma/plasmacytoma. In another embodiment, the lymphoma is a mantle cell lymphoma. In another embodiment, the

lymphoma is a mediastinal large B-cell lymphoma. In another embodiment, the lymphoma is an intravascular large B-cell lymphoma. In another embodiment, the lymphoma is a primary effusion lymphoma. In another embodiment, the lymphoma is a lymphomatoid granulomatosis. In another embodiment, the lymphoma is a post-transplant lymphoproliferative disorder. In another embodiment, the lymphoma is a T-cell neoplasm. In another embodiment, the lymphoma is a Natural Killer (NK) cell neoplasm. In another embodiment, the lymphoma is a precursor T cell neoplasm. In another embodiment, the lymphoma is a precursor T-lymphoblastic lymphoma/leukemia. In another embodiment, the lymphoma is a blastic NK lymphoma. In another embodiment, the lymphoma is a mature (peripheral) T cell neoplasm. In another embodiment, the lymphoma is a mature NK-cell neoplasm. In another embodiment, the lymphoma is a T-cell prolymphocytic leukemia. In another embodiment, the lymphoma is a T-cell granular lymphocytic leukemia. In another embodiment, the lymphoma is an aggressive NK cell leukemia. In another embodiment, the lymphoma is an (HTLV1+) Adult T cell lymphoma/leukemia. In another embodiment, the lymphoma is an extranodal NK/T-cell lymphoma of the nasal type. In another embodiment, the lymphoma is an enteropathy-type T-cell lymphoma. In another embodiment, the lymphoma is a hepatosplenic gamma-delta T-cell lymphoma. In another embodiment, the lymphoma is a subcutaneous panniculitis-like T-cell lymphoma. In another embodiment, the lymphoma is a mycosis fungoides/Sézary's syndrome. In another embodiment, the lymphoma is a primary cutaneous anaplastic large cell lymphoma of the T cell variety. In another embodiment, the lymphoma is a primary cutaneous anaplastic large cell lymphoma of the null cell variety. In another embodiment, the lymphoma is an unspecified peripheral T cell lymphoma. In another embodiment, the lymphoma is an angioimmunoblastic T cell lymphoma. In another embodiment, the lymphoma is a primary systemic anaplastic large cell lymphoma of the T cell variety. In another embodiment, the lymphoma is a primary systemic anaplastic large cell lymphoma of the null cell variety. In another embodiment, the lymphoma is a lymphomatoid papulosis. In another embodiment, the lymphoma is an

intermediate grade lymphoma. In another embodiment, the lymphoma is a high grade lymphoma. In another embodiment, the lymphoma is an indolent lymphoma. In another embodiment, the lymphoma is an aggressive lymphoma. In another embodiment, the lymphoma is any other type of lymphoma known in the art. Each type of lymphoma  
5 represents a separate embodiment of the present invention.

[00056] In another embodiment, the present invention provides an isolated nucleic acid molecule having a sequence selected from the sequences set forth in SEQ ID No: 1-10. In another embodiment, the present invention provides an isolated nucleic acid molecule having a sequence complementary to a sequence selected from the sequences set forth in  
10 SEQ ID No: 1-10.

[00057] In another embodiment, the present invention provides an siRNA molecule having a sequence corresponding to a fragment of an isolated nucleic acid molecule of the present invention. In one embodiment, the fragment is about 21-23 nucleotide in length. In another embodiment, the fragment is an accessible fragment.

15 [00058] In another embodiment, the present invention provides an shRNA molecule comprising a sequence corresponding to a fragment of an isolated nucleic acid molecule of the present invention. In one embodiment, the fragment is about 19-23 nucleotide in length. In another embodiment, the fragment is an accessible fragment.

[00059] In another embodiment, the present invention provides an ODN molecule having a  
20 sequence corresponding to an isolated nucleic acid molecule of the present invention or a fragment thereof. In one embodiment, the fragment is about 21-23 nucleotide in length. In another embodiment, the fragment is an accessible fragment.

[00060] In one embodiment, the length of the fragment of the isolated nucleic acid molecule wherefrom an ODN, siRNA, or shRNA of the present invention is derived is 21-23  
25 nucleotides. In another embodiment, the fragment is about 19 nucleotide in length. In



another embodiment, the fragment is about 21 nucleotide in length. In another embodiment, the fragment is about 23 nucleotide in length. In another embodiment, the fragment is about 25 nucleotide in length.

[00061] In one embodiment, the nucleic acid molecule of methods and compositions of the present invention is an oligo-deoxyribonucleic acid (ODN) molecule. short interfering RNA (siRNA) molecule; short hairpin RNA (shRNA) In another embodiment, the nucleic acid molecule is any other type of nucleic acid molecule known in the art.

[00062] In one embodiment, the nucleotide of methods and compositions of the present invention is an antisense nucleotide. In one embodiment, the antisense nucleotide is an antisense RNA. In another embodiment, the antisense nucleotide is an siRNA. In another embodiment, the antisense nucleotide is a short hairpin RNA (shRNA). siRNA and shRNA are short RNA sequences that induce sequence-specific RNA degradation when introduced into a cell. The use of siRNA and hairpin RNA is well known in the art, and is described, for example, in Yu J et al (Proc Natl Acad Sci 99(9): 6047-52, 2002). In another embodiment, the antisense nucleotide is a ribozyme. In another embodiment, the antisense nucleotide is a DNAzyme. In another embodiment, the antisense nucleotide is an antisense DNA. In another embodiment, the antisense nucleotide is any other type of nucleic acid molecule capable of destabilizing mRNA known in the art. Each possibility represents a separate embodiment of the present invention.

[00063] In another embodiment, "nucleic acid" refers to a string of at least two base-sugar-phosphate combinations. The term includes, in one embodiment, DNA and RNA. "Nucleotides" refers, in one embodiment, to the monomeric units of nucleic acid polymers. RNA may be, in another embodiment, in the form of a tRNA (transfer RNA), snRNA (small nuclear RNA), rRNA (ribosomal RNA), micro RNA (miRNA) and ribozymes. The use of siRNA and miRNA has been described (Caudy AA et al, Genes & Devel 16: 2491-96 and references cited therein). DNA may be in form of plasmid DNA, viral DNA, linear DNA, or

chromosomal DNA or derivatives of these groups. In addition, these forms of DNA and RNA may be single, double, triple, or quadruple stranded. The term also includes, in another embodiment, artificial nucleic acids that may contain other types of backbones but the same bases. In one embodiment, the artificial nucleic acid is a PNA (peptide nucleic acid). In  
5 another embodiment, the nucleotide is oxetane modified. In another embodiment, the nucleotide is modified by replacement of one or more phosphodiester bonds with a phosphorothioate bond (Example 2). PNA contain peptide backbones and nucleotide bases and are able, in one embodiment, to bind both DNA and RNA molecules. In another embodiment, the artificial nucleic acid contains any other variant of the phosphate backbone  
10 of native nucleic acids known in the art. The use of phosphothiorate nucleic acids and PNA are known to those skilled in the art, and are described in, for example, Neilsen PE, Curr Opin Struct Biol 9:353-57; and Raz NK et al Biochem Biophys Res Commun. 297:1075-84. The production and use of nucleic acids is known to those skilled in art and is described, for example, in Molecular Cloning, (2001), Sambrook and Russell, eds. and Methods in  
15 Enzymology: Methods for molecular cloning in eukaryotic cells (2003) Purchio and G. C. Fareed, eds. Each nucleic acid derivative represents a separate embodiment of the present invention.

[00064] In another embodiment, the nucleotide molecule of methods and compositions of the present invention is homologous to a nucleotide molecule disclosed herein. The terms  
20 "homology," "homologous," etc, when in reference to any protein or peptide, refer, in one embodiment, to a percentage of amino acid residues in the candidate sequence that are identical with the residues of a corresponding native polypeptide, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity. Methods  
25 and computer programs for the alignment are well known in the art.

[00065] In another embodiment, the term "homology," when in reference to any nucleic acid

sequence similarly indicates a percentage of nucleotides in a candidate sequence that are identical with the nucleotides of a corresponding native nucleic acid sequence.

[00066] Homology is, in one embodiment, determined by computer algorithm for sequence alignment, by methods well described in the art. For example, computer algorithm analysis of nucleic acid sequence homology may include the utilization of any number of software packages available, such as, for example, the BLAST, DOMAIN, BEAUTY (BLAST Enhanced Alignment Utility), GENPEPT and TREMBL packages.

[00067] In another embodiment, "homology" refers to identity to a sequence selected from SEQ ID No: 1-11 of greater than 70%. In another embodiment, "homology" refers to identity to a sequence selected from SEQ ID No: 1-11 of greater than 72%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 1-11 of greater than 75%. In another embodiment, "homology" refers to identity to a sequence selected from SEQ ID No: 1-11 of greater than 78%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 1-11 of greater than 80%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 1-11 of greater than 82%. In another embodiment, "homology" refers to identity to a sequence selected from SEQ ID No: 1-11 of greater than 83%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 1-11 of greater than 85%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 1-11 of greater than 87%. In another embodiment, "homology" refers to identity to a sequence selected from SEQ ID No: 1-11 of greater than 88%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 1-11 of greater than 90%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 1-11 of greater than 92%. In another embodiment, "homology" refers to identity to a sequence selected from SEQ ID No: 1-11 of greater than 93%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 1-11 of greater than 95%. In another embodiment, "homology" refers to identity to a sequence selected from SEQ ID No: 1-11 of greater than 96%. In another

embodiment, "homology" refers to identity to one of SEQ ID No: 1-11 of greater than 97%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 1-11 of greater than 98%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 1-11 of greater than 99%. In another embodiment, "homology" refers to identity to one of SEQ ID No: 1-11 of 100%.

[00068] In another embodiment, homology is determined via determination of candidate sequence hybridization, methods of which are well described in the art (See, for example, "Nucleic Acid Hybridization" Hames, B. D., and Higgins S. J., Eds. (1985); Sambrook et al., 2001, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, NY; and Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y). For example methods of hybridization may be carried out under moderate to stringent conditions, to the complement of a DNA encoding a native caspase peptide. Hybridization conditions being, for example, overnight incubation at 42 °C in a solution comprising: 10-20 % formamide, 5 X SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 X Denhardt's solution, 10 % dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA.

[00069] Protein and/or peptide homology for any amino acid sequence listed herein is determined, in one embodiment, by methods well described in the art, including immunoblot analysis, or via computer algorithm analysis of amino acid sequences, utilizing any of a number of software packages available, via established methods. Some of these packages may include the FASTA, BLAST, MPsrch or Scanps packages, and may employ the use of the Smith and Waterman algorithms, and/or global/local or BLOCKS alignments for analysis, for example. Each method of determining homology represents a separate embodiment of the present invention.

[00070] In another embodiment, the present invention provides a composition comprising an isolated nucleic acid molecule of the present invention.

[00071] In another embodiment, the present invention provides a vector comprising an isolated nucleic acid molecule of the present invention. In another embodiment, the present invention provides a composition comprising a vector of the present invention.

5 [00072] In another embodiment, the present invention provides a cell comprising an isolated nucleic acid molecule of the present invention. In another embodiment, the present invention provides a composition comprising a cell of the present invention.

[00073] In another embodiment, the present invention provides a kit comprising a reagent utilized in performing a method of the present invention. In another embodiment, the present invention provides a kit comprising an isolated nucleic acid of the present invention.  
10 In another embodiment, the present invention provides a kit comprising a vector of the present invention. In another embodiment, the present invention provides a kit comprising a cell of the present invention. In another embodiment, the present invention provides a kit comprising a composition of the present invention.

[00074] In another embodiment, a method of the present invention is used to treat minimal  
15 or residual lymphoma. Methods for detecting minimal lymphoma are well known in the art, and are described, for example in Sharp JG et al (Cancer Metastasis Rev 18(1):127-42, 1999). Each method represents a separate embodiment of the present invention.

[00075] In one embodiment, a treatment protocol of the present invention is therapeutic. In another embodiment, the protocol is prophylactic. In one embodiment, a composition of the  
20 present invention may be administered to a subject having a cancer that does not comprise a bcl-6 expressing cell, to prevent the development of bcl-6-expressing clones of the cancer. Each possibility represents a separate embodiment of the present invention.

[00076] In another embodiment, a method of the present invention utilizes an siRNA or shRNA not disclosed herein that is derived from an accessible region of the bcl-6 mRNA.  
25 Examples 5 and 6 describe methods of generation and testing of novel siRNA or shRNA

derived from an accessible region of the bcl-6 mRNA.

[00077] In another embodiment, the present invention provides the use of a composition that reduces an amount of the bcl-6 protein or of a RNA molecule encoding the bcl-6 protein in the manufacture of a medicament for treating a cancer comprising a bcl-6-expressing cell.

5 [00078] In another embodiment, the present invention provides the use of a composition comprising a nucleic acid molecule complementary to a region of a RNA molecule encoding the bcl-6 protein in the manufacture of a medicament for treating a cancer comprising a bcl-6-expressing cell.

10 [00079] In another embodiment, the present invention provides the use of a composition comprising a nucleic acid molecule corresponding to a region of a RNA molecule encoding the bcl-6 protein in the manufacture of a medicament for treating a cancer comprising a bcl-6-expressing cell.

15 [00080] In another embodiment, the present invention provides the use of a vector expressing a nucleic acid molecule complementary to a region of a RNA molecule encoding the bcl-6 protein in the manufacture of a medicament for treating a cancer comprising a bcl-6-expressing cell.

20 [00081] In another embodiment, the present invention provides the use of a vector expressing a nucleic acid molecule corresponding to a region of a RNA molecule encoding the bcl-6 protein in the manufacture of a medicament for treating a cancer comprising a bcl-6-expressing cell.

[00082] In one embodiment, the term "contacting" or "administering" refers to a method of exposure, which may be direct or indirect. In one method such contact comprises direct injection of a cell or tumor through any means well known in the art, such as microinjection. It is also envisaged, in another embodiment, that supply to the cell or tumor is indirect, such

as via administration to a subject, provision in a culture medium that surrounds the cell, or via any route known in the art. In another embodiment, the term "contacting" means that the nucleotide molecule of the present invention is introduced into a subject receiving treatment, and the nucleotide molecule is allowed to come in contact with the tumor *in vivo*.

5 [00083] In another embodiment, "contacting" refers to introducing the anti-estrogen compound of the present invention into a sample containing the enzyme in a test tube, flask, tissue culture, chip, array, plate, microplate, capillary, or the like, and incubated at a temperature and time sufficient to permit uptake of the nucleotide molecule by the cell. Methods for contacting the samples with the nucleotide are known to those skilled in the art  
10 and may be selected depending on the type of assay protocol to be run. Incubation methods are also known to those skilled in the art. Each possibility represents a separate embodiment of the present invention.

#### **Pharmaceutical Compositions**

[00084] "Pharmaceutical composition" refers, in one embodiment, to a therapeutically  
15 effective amount of the active ingredient, i.e. the nucleotide, together with a pharmaceutically acceptable carrier or diluent. A "therapeutically effective amount" refers, in one embodiment, to that amount which provides a therapeutic effect for a given condition and administration regimen.

[00085] The pharmaceutical compositions containing the nucleotide can be administered to a  
20 subject by any method known to a person skilled in the art, such as intra-tumorally, parenterally, paracancerally, transmucosally, transdermally, intramuscularly, intravenously, intra-dermally, subcutaneously, intra-peritoneally, intra-ventricularly, intra-cranially, or intra-vaginally.

[00086] In one embodiment, the pharmaceutical compositions are administered orally, and  
25 are thus formulated in a form suitable for oral administration, i.e. as a solid or a liquid

preparation. Suitable solid oral formulations include tablets, capsules, pills, granules, pellets and the like. Suitable liquid oral formulations include solutions, suspensions, dispersions, emulsions, oils and the like. In one embodiment of the present invention, the nucleotide molecules are formulated in a capsule. In accordance with this embodiment, the compositions of the present invention comprise, in addition to the nucleotide active compound and the inert carrier or diluent, a hard gelating capsule.

[00087] Further, in another embodiment, the pharmaceutical compositions are administered by intravenous, intraarterial, or intramuscular injection of a liquid preparation. Suitable liquid formulations include solutions, suspensions, dispersions, emulsions, oils and the like. In one embodiment, the pharmaceutical compositions are administered intravenously and are thus formulated in a form suitable for intravenous administration. In another embodiment, the pharmaceutical compositions are administered intraarterially and are thus formulated in a form suitable for intraarterial administration. In another embodiment, the pharmaceutical compositions are administered intramuscularly and are thus formulated in a form suitable for intramuscular administration.

[00088] Further, in another embodiment, the pharmaceutical compositions are administered topically to body surfaces and are thus formulated in a form suitable for topical administration. Suitable topical formulations include gels, ointments, creams, lotions, drops and the like. For topical administration, the nucleotide agents or their physiologically tolerated derivatives such as salts, esters, N-oxides, and the like are prepared and applied as solutions, suspensions, or emulsions in a physiologically acceptable diluent with or without a pharmaceutical carrier.

[00089] Further, in another embodiment, the pharmaceutical compositions are administered as a suppository, for example a rectal suppository or a urethral suppository. Further, in another embodiment, the pharmaceutical compositions are administered by subcutaneous



implantation of a pellet. In a further embodiment, the pellet provides for controlled release of nucleotide agent over a period of time.

[00090] In another embodiment, the active compound is delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the  
5 Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*).

[00091] As used herein "pharmaceutically acceptable carriers or diluents" are well known to those skilled in the art. The carrier or diluent may be a solid carrier or diluent for solid formulations, a liquid carrier or diluent for liquid formulations, or mixtures thereof.

10 [00092] Solid carriers/diluents include, but are not limited to, a gum, a starch (e.g. corn starch, pregeletanized starch), a sugar (e.g., lactose, mannitol, sucrose, dextrose), a cellulosic material (e.g. microcrystalline cellulose), an acrylate (e.g. polymethylacrylate), calcium carbonate, magnesium oxide, talc, or mixtures thereof.

[00093] For liquid formulations, pharmaceutically acceptable carriers may be aqueous or  
15 non-aqueous solutions, suspensions, emulsions or oils. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Examples of oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, mineral oil, olive oil,  
20 sunflower oil, and fish-liver oil.

[00094] Parenteral vehicles (for subcutaneous, intravenous, intraarterial, or intramuscular injection) include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's and fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like.  
25 Examples are sterile liquids such as water and oils, with or without the addition of a

surfactant and other pharmaceutically acceptable adjuvants. In general, water, saline, aqueous dextrose and related sugar solutions, and glycols such as propylene glycols or polyethylene glycol are preferred liquid carriers, particularly for injectable solutions. Examples of oils are those of petroleum, animal, vegetable, or synthetic origin, for example, 5 peanut oil, soybean oil, mineral oil, olive oil, sunflower oil, and fish-liver oil.

[00095] In addition, the compositions may further comprise binders (e.g. acacia, cornstarch, gelatin, carbomer, ethyl cellulose, guar gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, povidone), disintegrating agents (e.g. cornstarch, potato starch, alginic acid, silicon dioxide, croscarmellose sodium, crospovidone, guar gum, sodium starch glycolate), 10 buffers (e.g., Tris-HCl, acetate, phosphate) of various pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), protease inhibitors, surfactants (e.g. sodium lauryl sulfate), permeation enhancers, solubilizing agents (e.g., glycerol, polyethylene glycerol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite, butylated hydroxyanisole), stabilizers 15 (e.g. hydroxypropyl cellulose, hydroxypropylmethyl cellulose), viscosity increasing agents (e.g. carbomer, colloidal silicon dioxide, ethyl cellulose, guar gum), sweeteners (e.g. aspartame, citric acid), preservatives (e.g., Thimerosal, benzyl alcohol, parabens), lubricants (e.g. stearic acid, magnesium stearate, polyethylene glycol, sodium lauryl sulfate), flow-aids (e.g. colloidal silicon dioxide), plasticizers (e.g. diethyl phthalate, triethyl citrate), 20 emulsifiers (e.g. carbomer, hydroxypropyl cellulose, sodium lauryl sulfate), polymer coatings (e.g., poloxamers or poloxamines), coating and film forming agents (e.g. ethyl cellulose, acrylates, polymethacrylates) and/or adjuvants.

[00096] In one embodiment, the pharmaceutical compositions provided herein are controlled-release compositions, i.e. compositions in which the nucleotide molecule is released over a 25 period of time after administration. Controlled- or sustained-release compositions include formulation in lipophilic depots (e.g. fatty acids, waxes, oils). In another embodiment, the

composition is an immediate-release composition, i.e. a composition in which all of the nucleotide molecule is released immediately after administration.

[00097] In another embodiment, the pharmaceutical composition can be delivered in a controlled release system. For example, the agent may be administered using intravenous  
5 infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other modes of administration. In one embodiment, a pump may be used (see Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989). In another embodiment, polymeric materials can be used. In yet another embodiment, a controlled release system can be placed in proximity to  
10 the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, *supra*, vol. 2, pp. 115-138 (1984). Other controlled-release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990).

[00098] The compositions also includes, in one embodiment, incorporation of the active  
15 material into or onto particulate preparations of polymeric compounds such as polylactic acid, polglycolic acid, hydrogels, etc, or onto liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts.) Such compositions will influence the physical state, solubility, stability, rate of *in vivo* release, and rate of *in vivo* clearance.

20 [00099] Also comprehended by the invention are particulate compositions coated with polymers (e.g. poloxamers or poloxamines) and the compound coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of tissue-specific receptors.

[000100] Also comprehended by the invention are compounds modified by the covalent  
25 attachment of water-soluble polymers such as polyethylene glycol, copolymers of

polyethylene glycol and polypropylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone or polyproline. The modified compounds are known to exhibit substantially longer half-lives in blood following intravenous injection than do the corresponding unmodified compounds (Abuchowski et al., 1981; Newmark et al., 1982; and  
5 Katre et al., 1987). Such modifications may also increase the compound's solubility in aqueous solution, eliminate aggregation, enhance the physical and chemical stability of the compound, and greatly reduce the immunogenicity and reactivity of the compound. As a result, the desired *in vivo* biological activity may be achieved by the administration of such polymer-compound adducts less frequently or in lower doses than with the unmodified  
10 compound.

[000101] The preparation of pharmaceutical compositions that contain an active component, for example by mixing, granulating, or tablet-forming processes, is well understood in the art. The active therapeutic ingredient is often mixed with excipients that are pharmaceutically acceptable and compatible with the active ingredient. For oral  
15 administration, the nucleotide agents or their physiologically tolerated derivatives such as salts, esters, N-oxides, and the like are mixed with additives customary for this purpose, such as vehicles, stabilizers, or inert diluents, and converted by customary methods into suitable forms for administration, such as tablets, coated tablets, hard or soft gelatin capsules, aqueous, alcoholic or oily solutions. For parenteral administration, the nucleotide  
20 agents or their physiologically tolerated derivatives such as salts, esters, N-oxides, and the like are converted into a solution, suspension, or emulsion, if desired with the substances customary and suitable for this purpose, for example, solubilizers or other substances.

[000102] An active component can be formulated into the composition as neutralized pharmaceutically acceptable salt forms. Pharmaceutically acceptable salts include the acid  
25 addition salts (formed with the free amino groups of the polypeptide or antibody molecule), which are formed with inorganic acids such as, for example, hydrochloric or phosphoric

acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed from the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the  
5 like.

[000103] For use in medicine, the salts of the nucleotides are pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts, which may,  
10 for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Each pharmaceutical carrier or excipient represents a separate embodiment of the present  
15 invention.

[000104] In one embodiment, the term "treating" refers to curing a disease. In another embodiment, "treating" refers to preventing a disease. In another embodiment, "treating" refers to reducing the incidence of a disease. In another embodiment, "treating" refers to inducing remission. In another embodiment, "treating" refers to slowing the progression of a  
20 disease. The terms "reducing", "suppressing" and "inhibiting" refer in one embodiment, to lessening or decreasing. The term "progression" may refer to increasing in scope or severity, advancing, growing or becoming worse. The term "recurrence" refers, in one embodiment, to the return of a disease after a remission.

[000105] In one embodiment, the term "administering" refers to bringing a subject in contact  
25 with a nucleotide molecule of the present invention. In another embodiment, administration is accomplished *in vitro*, i.e. in a test tube. In another embodiment, administration is

accomplished *in vivo*, i.e. in cells or tissues of a living organism. Each possibility represents a separate embodiment of the present invention.

[000106] In one embodiment, the methods of the present invention comprise administering an nucleotide molecule as the sole active ingredient. However, also encompassed within the scope of the present invention are methods that comprise administering the nucleotide molecules in combination with one or more therapeutic agents. These agents include, but are not limited to, various cancer chemotherapy agents and other pharmaceutical compounds known in the art to be administered together with cancer chemotherapy agents.

## **EXPERIMENTAL DETAILS SECTION**

### **EXAMPLE 1**

#### **IDENTIFICATION OF ACCESSIBLE REGIONS OF BCL-6 RNA**

#### **MATERIALS AND EXPERIMENTAL METHODS**

##### ***Cells***

[000107] Bcl-6 expressing Louckes cells were obtained from Jill Lacy, Yale University. K562 cells were used as a negative control for cells not expressing bcl-6. Cells were maintained in RPMI 1640 media supplemented with 10% FBS and 0.5% pencillin/ streptomycin.

##### ***Cloning and in vitro transcription***

[000108] An insert containing full length (2.4 kilobase) bcl-6 coding sequence, obtained from R. Dalla-Favera, Columbia University) was sub-cloned into a pcDNA3 plasmid (Invitrogen, Carlsbad, California) using the KpnI and HindIII cloning sites. RNA was transcribed from linearized plasmids using the T7 RNA Polymerase RiboMax™ Kit (Promega). Transcribed bcl-6 mRNA was used for subsequent experiments.

***ODNs and synthesis of SQRM***

[000109] SQRM ODNs were synthesized in the University of Pennsylvania Cancer Center Nucleic Acid Facility on an Expedite™8909 Nucleic Acid Synthesis System (Applied Biosystems) using standard phosphoramidite chemistry; bcl-6 antisense ODNs were (AS ODNs) obtained from Integrated DNA Technologies]. The SQRM complements to the AccessSearch outputted RNA sequences are synthesized with 30-C7-4-(4'-dimethylaminophenylazo)benzoic acid (DABCYL) ControlledPore Glass (Glen Research) used as support and a fluoresceinphosphoramidite (Cruachem) for 5' end modification (Table 1). All ODNs and SQRMs were HPLC-purified. SQRMs were numbered according to the following convention: the SQRM's number designator corresponds to the 5' base of mRNA to which the 3' base of the SQRM complements, the adenine of the initiation codon is base (+1), and the base 5' of the initiation A is designated (-1), no zero base. The full descriptor is characterized by the number of the first 5' RNA base involved in a duplex with the probe, an arrow to indicate the direction of hybridization of the probe to the mRNA and a second number that corresponds to the 3'-most base involved in the helix.

***Fluorescence hybridization assays***

[000110] SQRMs (100 nM) were incubated for 30 min at 37° C with (1 mM) *in vitro* transcribed RNA, (10 mM) complementary ODN (positive control) or (1 mM) scrambled ODN (negative control) target in SQRM buffer (100 mM Tris-HCl, pH 7.5, 2 mM MgCl<sub>2</sub>). 'Scrambled' ODNs were designed by replacing each base with its complementary base in the same 5' to 3' direction. The fluorescence was monitored in a plate reader equilibrated to 37° C. Signal-to-noise ratios for all reactions can be found in Table 2.

[000111] Total RNA was isolated from Louckes cells and K562 cells with QIAgen RNeasy Kit (Qiagen). Fluorescence emission was monitored using a Packard FluoroCount Microplate Fluorometer (Packard Instrument Company).

***RNaseH cleaving assay***

[000112] 1  $\mu$ M of SQRM was pre-incubated with 1  $\mu$ M bcl-6 mRNA in the presence of 100 mM Tris and 2 mM MgCl at 37°C for 10 min to allow hybridization to occur. RNaseH buffer and enzyme were added, and the mixture was incubated for another 10 min at 37°C.

5 The reaction was stopped by adding Proteinase K, and the whole reaction mixture was resolved on a 1% agarose gel. In this case the bcl-6 mRNA was generated by rabbit reticulocyte lysate transcription/translation system. This system was employed to model the effect that cellular proteins might have on ODN hybridization. Equal amounts of post-translation product from each reaction mixture were analyzed by electrophoresis in a single

10 polyacrylamide gel, followed by PhosphorImager® analysis.

***Preparation of total cellular RNA***

[000113] Total RNA was isolated from cells using a Qiagen (Valencia, CA) mini kit, and the yield measured spectrophotometry. A total amount of 20,000  $\mu$ g and 40,000  $\mu$ g RNA was incubated in the fluorimeter with SQRM and compared with background fluorescence,

15 fluorescence of the negative control, and fluorescence of the SQRM with 1  $\mu$ g *in vitro*-transcribed bcl-6 RNA.

**RESULTS**

[000114] In order to identify regions of bcl-6 RNA that are accessible to hybridization, a computer-driven search algorithm was used to identify 20-35 base pair (bp) sequences with

20 palindromic regions of 4-6 bp in length, within the bcl-6 sequence. 10 such sequences were identified, and SQRM complementary to the sequences were designed; these are depicted in Table 1. Figure 1 shows a schematic depiction of the SQRM mechanism.

[000115] Table 1: SQRM sequences. In each case, the SQRM was modified with fluorescein on the 5' end and DABCYL on the 3' end.



Name	SEQ ID No:	Sequence
518-548	1	5'-CTGGGGGCAAAGGCTCTGCTCTCACACCCAG-3'
831-864	2	5'-GGCTGAGGGGGCAGCAGGTTTGAGGCCCTCAGCC-3'
832-863	3	5'-GCTGAGGGGGCAGCAGGTTTGAGGCCCTCAGC-3'
834-861	4	5'-TGAGGGGGCAGCAGGTTTGAGGCCCTCA-3'
1039-1073	5	5'-GCCTGGAGGATGCAGGCATTCTTACTGCTGCAGGC-3'
1190-1222	6	5'-AGGCTCGTGGGGAAAGGCGGCCAGCTCAGCCT-3'
1367-1392	7	5'-GCTCTCGCTGCTGCTGCGGGGAGAGC-3'
1816-1841	8	5'-ACCTGTACAAATCTGGCTCCGCAGGT-3'
1821-1853	9	5'-CGGAGGTGGGCCACCTGTACAAATCTGGCTCCG-3'
2121-2141	10	5'-AAGCATCAACACTCCATGCTT-3'
Scramble	33	5'-TGTCTGGTTGCAAAGCCTGGCATAAAGACA-3'

[000116] Table 2. Signal-to-noise ratios.

SQRM	RNA	ODN	SQR
518-548	2.3 +/- 0.8	70.6 +/- 16.0	2.0 +/- 0.6
831-864	1.8 +/- 0.2	33.0 +/- 4.2	1.3 +/- 0.2
832-863	1.1 +/- 0.1	57.6 +/- 6.6	1.6 +/- 0.2
834-861	4.4 +/- 2.4	150.6 +/- 61.2	1.9 +/- 0.8
1039-1073	2.2 +/- 0.5	39.2 +/- 8.6	2.7 +/- 0.6
1190-1222	14.5 +/- 1.6	57.6 +/- 5.6	2.2 +/- 0.4
1367-1392	1.1 +/- 0.3	51.1 +/- 13.7	2.0 +/- 0.4
1816-1841	1.2 +/- 0.3	17.8 +/- 3.5	2.5 +/- 0.5
1821-1853	3.2 +/- 1.2	63.0 +/- 7.8	3.3 +/- 2.3
2121-2141	3.8 +/- 1.9	207.0 +/- 22.9	2.9 +/- 1.0

[000117] Ten SQRMs (self-quenching reporter molecules) each were synthesized to map the

full-length, 2.4 kb, bcl-6 mRNA SQRM 1190-1222 showed a favorable signal to- noise ratio (14.5 (+/- 1.5):1; Figure 2). Hybridization of SQRM 1190-1222 with the bcl-6 transcript was confirmed using an *in vitro* RNaseH cleaving assay. *In vitro*-transcribed mRNA was incubated with SQRM 1190-1222, or with two sense SQRM corresponding to non-opening  
5 locations 831-864 and 1367-1392, which yielded fragments of the expected size (1.1 and 1.3 kDa; Figure 3A). Specificity of cutting was demonstrated by the fact that neither of the control sequences had any effect on the mRNA; bcl-6 mRNA incubated with these ODN, or with enzyme alone, remained intact.

[000118] Next, SQRM 1190-1222 was incubated with total cellular RNA derived from  
10 Louckes Burkitt's Lymphoma cells, which express the bcl-6 gene, and K562 BCR/ABL-1 (+) myeloid leukemia cells, which do not. Fluorescence was monitored using a plate reader. An ODN completely complementary to the SQRM served as the arbitrary 100% fluorescence control. As expected, SQRM fluorescence increased in the Louckes cell RNA when compared with that observed in the K562 RNA. Specificity was further demonstrated  
15 by the observation that fluorescence was proportional to the amount of RNA in which the SQRM was incubated. The signal to- noise ratio for SQRM 1190-1222 when incubated in 40 mg of Louckes RNA was 2-fold higher than when incubated in 20 mg of RNA (Figure 3B).

[000119] These findings demonstrate that bcl-6 mRNA contains regions that are available for  
20 hybridization, and that one such region is the region complementary to AGGCTCGTGGGGAAAGGCGGCCAGCTCAGCCT (SQRM-1190-1222; SEQ ID No: 6).

**EXAMPLE 2****ANTISENSE OLIGO-DEOXYNUCLEOTIDES COMPLEMENTARY TO BCL-6  
RNA DECREASE VIABILITY OF LYMPHOMA CELLS AND THEIR BCL-6  
EXPRESSION****MATERIALS AND EXPERIMENTAL METHODS*****ODN***

[000120] Antisense ODN were synthesized and purified by Integrated DNA Technologies (Coralville, IA). At the 3' and 5' end of each molecule were 5 phosphorothioate bonds; the intervening bonds were phosphodiester. siRNA molecules were synthesized, HPLC purified, deprotected and annealed by Dharmacon (Lafayette, Colorado).

***Viability assays***

[000121] 5 µg ODN or siRNA was transfected into Louckes cells using an Amaxa nucleoporation. Immediately afterwards,  $1.5 \times 10^6$  cells were placed in 1.5 mL fresh media and cultured for 6 hours (ODN) or 48 hours (siRNA). Viability of cells was assessed by trypan blue exclusion. Transfection efficiency was about 95%, and cell viability was over 90% (depicted in Figure 4).

***Reverse transcription and real-time PCR***

[000122] Cells were washed twice in PBS and total RNA was isolated as described above. The RNA was treated with RQ-DNAse and re-purified with the Qiagen kit. The reverse transcription was performed in 20 µL total volume with 300 ng of RNA using M-MLV Reverse transcriptase (Invitrogen) and random hexamers at 10 mM concentration. Then 1 µL of cDNA was used for the real time PCR reaction. The reaction was performed in triplicates each time for bcl-6 and 18S as an internal standard. The negative control was

RNA (no RT reaction). Antisense ODN and siRNA stored in nuclease-free water at -80°C. Control cells were subjected to the nucleofection procedure but in the absence of ODN.

[000123] Primers and probe for the Real Time PCR were designed with Molecular Beacon Program from BioRad and synthesized and HPLC purified by Nucleic Acid Facility of the University of Pennsylvania). The sequences were as follows:

- [000124] **For bcl-6:** Forward primer: 5'- CCA ACC AAG CTG AGT GCC AG (SEQ ID No: 12); Reverse primer: 5'- GGT GCA TGT AGA GTG GTG AGT G (SEQ ID No: 13); probe: 5'-CTC CAC CAT CCC ACA AGC CAG CCG (SEQ ID No: 14). The probe was labeled with FAM at 5' end and Black whole1 quencher at the 3' end.
- 10 [000125] **For 18S:** Forward primer: 5'- GGA CAT CTA AGG GCA TCA CAG ACC-3' (SEQ ID No: 15); Reverse primer: 5'-TGA CTC AAC ACG GGA AAC CTC AC-3' (SEQ ID No: 16); probe: 5'- TGG CTG AAC GCC ACT TGT CCC TCT AA-3' (SEQ ID No: 17). (FAM at the 5' end and TAMRA quencher at the 3' end)- hybridizes between 1294 and 1614 to human 18S.
- 15 [000126] The protocol for PCR reaction consisted of: 50°C for 2 min, and denaturation at 95°C for 10 min, followed by 36 cycles of 15 sec denaturation at 92°C and 1 min of annealing and elongation at 60°C. The expected 133 bp bcl-6 PCR product was resolved on 1% agarose gel to confirm the specificity of the reaction.

#### *Western blot*

- 20 [000127] Cells incubated for the appropriate time with nucleic acid molecules were washed and lysed in triple lysis buffer to obtain a total (nuclear and cytoplasmic) protein cell extract. In each case equal amount (100 µg) of the total protein was resolved on 10% polyacrylamide gel and transferred to the PVDF membrane and then probed with the primary antibody against bcl-6 (rabbit polyclonal, C-19, Santa Cruz Biotechnology) at 1:500 dilution from at
- 25 4°C overnight. After 3 washes in TBS-T buffer the secondary antibody (anti-rabbit, HRP

conjugated; 1:1000 dilution) was incubated with the membrane for 1 hour at room temperature. The visualization was performed with ECL (+) reagent. The same PVDF membrane was then stripped with stripping buffer and probed with antibody against beta actin (1: 3000 dilution).

5

## RESULTS

[000128] Next, antisense oligo-deoxynucleotides (ODN) corresponding to the sequences of the SQRM were transfected into bcl-6 expressing Louckes (Burkitt's lymphoma) cells and cell viability was determined for four consecutive days. Cells transfected with SQRM-1190-1222 exhibited a 50% drop in viability within 24 hours (Figure 5). A smaller, but persistent effect on viability was seen with SQRM-1367-1392. SQRM-1190-1222 and SQRM-1367-1392 also caused 7-fold and 2.5-fold decreases in bcl-6 mRNA expression, respectively (Figure 6). A smaller but significant decrease in bcl-6 mRNA expression was observed with SQRM -2121-2141. The effects on bcl-6 mRNA expression were confirmed by Western blot, which demonstrated an 80% decrease of bcl-6 proteins levels upon incubation with SQRM-1190-1222 (Figure 7).

10  
15

[000129] These findings show that bcl-6 mRNA expression can be reduced by introduction of antisense ODN complementary to the bcl-6 sequence. The findings further show that introduction of the antisense ODN can reduce the viability of bcl-6-expressing lymphoma cells.

### EXAMPLE 3

#### SHORT INTERFERING RNA MOLECULES CORRESPONDING TO BCL-6 RNA SEQUENCE DECREASE VIABILITY OF LYMPHOMA CELLS AND THEIR BCL-6 EXPRESSION

5. [000130] Next, small interfering RNA molecules (siRNA) corresponding to segments of bcl-6 RNA sequence were synthesized and incubated with Louckes cells, and bcl-6 expression assayed by Western blot. siRNA corresponding to SQRM-1190-1222 reduced bcl-6 mRNA expression by three-fold, in a dose-dependent manner (Figure 8). These findings were confirmed by Western blot, which revealed an effect of siRNA corresponding to both  
10 SQRM-2121 and SQRM-1367 on bcl-6 protein expression (Figure 9).

[000131] These findings demonstrate that siRNA corresponding to segments of bcl-6 RNA sequence can reduce bcl-6 mRNA and protein expression in bcl-6-expressing lymphoma cells.

### EXAMPLE 4

#### 15 LENTIVIRUSES EXPRESSING SHORT HAIRPIN SEQUENCES COMPLEMENTARY TO BCL mRNA DECREASE VIABILITY OF LYMPHOMA CELLS AND THEIR BCL-6 EXPRESSION

[000132] Region 2121 was converted to a short hairpin RNA (shRNA) sequence suitable for expression in a GFP/lentiviral vector. The shRNA sequence was subcloned into a  
20 GFP/lentiviral vector and used to transfect Ly7 DLBCL cells and bcl-6 mRNA levels in GFP-positive cells assessed. shRNA expressing lentivirus decreased bcl-6 mRNA levels 60-

fold, whereas wild-type lentivirus had no measurable effect (Figure 10A). The shRNA expressing lentivirus, but not the wild-type virus, induced apoptosis in 50% of the Ly7 cells, as detected by ethidium bromide/ acridine orange staining (Figure 10B).

[000133] The findings of this Example demonstrate that expression of shRNA derived from accessible regions of bcl-6 mRNA decreases bcl-6 expression and induces apoptosis in lymphoma cells.

### **EXAMPLE 5**

#### **IDENTIFICATION OF ADDITIONAL siRNA SEQUENCES CORRESPONDING TO ACCESSIBLE REGIONS OF BCL-6 mRNA**

[000134] 21-nucleotide (nt) fragments of the accessible regions of bcl-6 depicted in Table 1 are synthesized and tested for their ability to reduce bcl-6 mRNA expression and reduce viability of lymphoma cells, by the methods of previous Examples. Several sequences that are found to be effective by transfection are subcloned into a lentiviral vector and added to lymphoma cells in culture. Lentiviral and other vectors expressing the effective sequences and other reagents comprising the effective sequences are administered to lymphoma patients, and are found to induce apoptosis in the lymphoma cells.

### **EXAMPLE 6**

#### **DERIVATION OF ADDITIONAL shRNA SEQUENCES CORRESPONDING TO ACCESSIBLE REGIONS OF BCL-6 mRNA**

[000135] ShRNA sequences corresponding to accessible regions of bcl-6 mRNA are derived using algorithms known in the art. Typical siRNA sequences have the following characteristics:

[000136] 1). Begins with a purine (G or A) residue; 2). Contains 5 bases for the restriction site overhang at the 5' end, followed by 19-23 bases of sense strand, 8-9 bases of hairpin loop, 19-23 bases of antisense strand, 6 bases of a unique restriction site, and 1-2 bases for pairing with the restriction site overhang on the complementary strand.

- 5 [000137] The 19-23 nucleotide sequence should have the following characteristics: 1). Is preferably 19 nucleotides in length. 2). Is not located within the 5' and 3' untranslated regions (UTRs) nor regions near the start codon (within 75 bases). 3). Does not contain a consecutive run of 3 or more thymidine residues. 4). Has a GC content of between 40% and 60%, preferably approximately 45%. 5) Preferably has at least 3 A or T residues in positions  
10 15-19 of the sense sequence. 6). Does not exhibit secondary structure. 7). Is specific for the gene of interest.

- [000138] Several candidate shRNA sequences are subcloned into a lentiviral expression vector, then tested for activity against lymphoma cells as described in the previous Example. shRNA-lentiviruses that kill lymphoma cells are administered to lymphoma patients, and are  
15 shown to have cancer chemotherapeutic activity.